Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies

Trial Profile

Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2019

At a glance

  • Drugs Rituximab (Primary) ; Glucocorticoids; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms BIORA
  • Sponsors Biocad
  • Most Recent Events

    • 15 Jun 2019 Results (n=54) assessing effect of Bcd-020 on Inflammatory and Immunological Biomarkers in Patients with Rheumatoid Arthritis presented at the 20th Annual Congress of the European League Against Rheumatism
    • 31 Aug 2018 Biomarkers information updated
    • 28 Aug 2016 Status changed from active, no longer recruiting to completed according to results presented at the 17th Annual congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top